Intensity Therapeutics (INTS) Appoints Thomas Dubin to Its Board

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. MSFT
3. GOOGL
4. EBAY
5. FTNT
6. TENB
7. KLAC
8. BIIB
9. CMG
10. ETSY

Go back to Intensity Therapeutics (INTS) Appoints Thomas Dubin to Its Board

Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors

May 15, 2024 8:01 AM EDT

SHELTON, Conn., May 15, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces the appointment of Thomas Dubin, J.D., MPH, to the Intensity Board of Directors, effective May 14,... More